Recent Finacing
Recent Raise
OnCusp Therapeutics in-licenses preclinical oncology assets (ADCs, bispecifics, small molecules) and advances them into early clinical development—CUSP06, a CDH6-targeting ADC, has FDA IND clearance and a planned U.S. Phase I.
